The effects of hyperglycemia on myocardial glucose metabolism were investigated in seven healthy male subjects (age 24±4 yr). I6-C4qGlucose and IU-'3Cilactate were infused as tracers. Circulating glucose was elevated to two hyperglycemic levels using a clamp technique for 1 h at each level. The mean arterial glucose concentration was 4.95±0.29 (control), 8.33±0.31 and 10.84±0.60 jumol/ml, respectively. Glucose extraction increased significantly from control (0.15±0.13 gsmol/ ml) during each level of the glucose clamp (0.28±0.12, P < 0.02, and 0.54±0.14 ;tmol/ml, P < 0.005, respectively). Myocardial production of '4CO2 showed that during control 9±10% of exogenous glucose was oxidized immediately upon extraction. Despite a significant increase in the amount of exogenous glucose oxidized with level II hyperglycemia, it represented only 32±10% of the glucose extracted.
Introduction
Hyperglycemic or euglycemic insulin clamp techniques have been used to investigate total body glucose uptake and oxidation, and glucose metabolism in skeletal muscle and other organ systems in healthy human subjects (1) (2) (3) (4) (5) (6) . However, little is known about the effects of hyperglycemia on glucose utilization in the hearts of intact animals and humans. Previous studies have measured the arterial (A)' and coronary sinus (CS) difference for glucose and have calculated an oxygen extraction ratio (OER); the OER is based on the assumption that the entire A -CS difference is oxidized. These calculations suggest that glucose contributes from 15 to 55% of oxidative metabolism under fasting conditions (7) (8) (9) (10) (11) (12) (13) (14) (15) . During acute hyperglycemia, the myocardial extraction ofglucose significantly increases; OER data obtained during hyperglycemia imply that glucose becomes the major substrate for oxidative metabolism under this condition (7-9, 12-13, 15) .
Numerous studies have examined the effects of elevated glucose during myocardial hypoxia or ischemia. The concept that glucose enhances myocardial function during pathologic conditions dates back to Goulston in 1911 (16). In 1914 Budingen reported that eight patients with severe angina or myocardial infarction improved after glucose infusion (17). Insulin was later given with glucose to promote glucose transport and potassium was added to maintain the circulating level and replace intracellular losses due to ischemia. In the 1960s SodiPallares further popularized this treatment initially for arrhythmias, and later for angina (18, 19) . Glucose-insulin-potassium infusions have been advocated for patients with acute myocardial infarctions by other investigators and have also been administered before cardiac surgery (20) (21) (22) (23) (24) (25) (26) (27) . Animal studies have shown that glucose infusions increase ATP levels and glycogen stores, and reduce tissue necrosis during acute infarctions (28) (29) (30) . Although several studies have demonstrated that elevating the circulating glucose concentration increases the A -CS glucose difference in humans with coronary disease (8, 31) , no study has assessed the activity ofthe various glycolytic pathways during hyperglycemia in healthy or ischemic human subjects. The effects of hyperglycemia on glucose oxidation, activity of the nonoxidative (anaerobic) pathway, and glycogen storage in the human myocardium is not known.
The purpose of this study was to evaluate the effects of acute short-term hyperglycemia on myocardial glucose metabolism in healthy young human subjects. Dual carbon-labeled isotopes ([6-'4C]glucose and [U-'3C]lactate) were used to quantitate myocardial glucose oxidation, lactate release and the contribution of exogenous glucose to lactate release. A hyperglycemic clamp technique was used to elevate and stabilize circulating glucose levels.
Methods
Subject selection. Young healthy male volunteers were sought. The volunteers underwent a complete medical history, physical examination, and laboratory tests. The tests included an electrocardiogram, complete blood count, liver function tests, blood urea nitrogen and creatinine determinations, urinalysis, and a fasting glucose. In addition, the subject had to complete at least stage V ofthe standard Bruce protocol (32) and achieve 95% ofhis maximal predicted heart rate on a treadmill exercise test. Subjects with a family history of diabetes or a history of chronic drug use or smoking were excluded. If there was no evidence of cardiac or any other major systemic illness and all the laboratory tests were within normal limits, the volunteer was accepted as a subject. The examination and exercise test were performed at least I wk before the metabolic study.
The protocol was approved by the Committees on Human Research ofthe University of California and the Veterans Administration Medical Center at San Francisco, CA. The use of radioisotopes was approved by the Radiation Safety Committee of the Veterans Administration Medical Center. Each subject was informed of the nature, purpose, and possible risks involved in the study before written consent was obtained.
Protocol. The subjects were instructed to maintain a regular diet; no dietary manipulations were performed. The subjects reported for the procedure at 8 a.m. after a 10-15-h fast. No premedication was given. A short Teflon catheter was inserted percutaneously into a left antecubital vein for isotope infusion. A local anesthetic (2% lidocaine) was used to perform a venous cutdown in the right arm; and a 7F thermodilution flow coronary sinus catheter (Webster Laboratories, Baldwin Park, CA) was inserted as previously published (33) . In addition, a long Teflon catheter was also inserted into this vein and placed in the mid-brachial region for the glucose infusion during the clamp protocol. A short polyethylene catheter was placed into the right brachial artery. At least 20 min is required to achieve equilibration of the arterial and coronary sinus specific activity and the myocardial CO2 pool when lactate is labeled with a tracer, and 25-30 min is required for a glucose tracer (33, 34) . Thus to ensure equilibration, the first control blood samples were obtained at 42.0±6.6 min after the priming bolus and the start of the continuous isotope infusion in this study.
Arterial and coronary sinus blood samples were drawn simultaneously. Samples were obtained for chemical concentrations of glucose, lactate, alanine, and FFA, specific activities ("1C) of glucose and lactate, '3C-enrichment of lactate, "'CO2, and the 02 content. In addition, arterial samples were drawn for insulin concentrations. Immediately after every metabolic blood sample, the heart rate, arterial pressure, and coronary sinus blood flow were recorded. Coronary sinus blood flow was determined by a thermodilution technique using room temperature normal saline infused at a rate of 46 ml/min (35) .
Two sets of samples were obtained during control (i.e., at fasting glucose concentrations) 10 min apart. The fasting arterial glucose was determined immediately using a glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH). In the subjects undergoing the hyperglycemic clamp protocol, the circulating glucose was elevated after the control samples by 60 mg/ 100 ml above the fasting concentration using the hyperglycemic clamp technique of DeFronzo et al. (1) When [6-"'C] glucose is used as a tracer, glucose oxidation (gmol/ ml) can be calculated from the myocardial production of "'CO2 and the arterial specific activity as (CS -A)"'C02 dpm/ml/arterial specific activity of glucose.
Since other substrates are labeled secondarily when tracers are infused, the (CS-A) "'CO2 was corrected for oxidation ofthe secondarily labeled substrates as previously published (33, 34) .
Using dual-carbon labeled isotopes of glucose and lactate and measuring the specific activities of glucose and lactate and the '3C enrichment of lactate in the artery and coronary sinus allows quantitation of the conversion of exogenous glucose to lactate by the myocardium as previously reported (33) .
The calculations for substrate contribution to myocardial oxidative metabolism were based on substrate extraction or glucose oxidation in tgmol/ml, and the arterial-coronary sinus difference in oxygen content for the same sampling period expressed in Mmol/ml. The oxygen equivalent (jsmol oxygen/flmol) is 6 for glucose, 3 for lactate, and 24.5 for FFA. The oxygen equivalent for the substrate was expressed as a percentage of the total oxygen difference in gmol/ml.
Myocardial oxygen consumption (mlmin) was calculated from the arterial and coronary sinus difference in the oxygen content (ml/100 ml) and the coronary sinus flow as (A -CS) 02 X CS flow.
Statistical analysis. To compare myocardial substrate extraction, oxidation and utilization, and hemodynamic parameters during the two levels ofthe glucose clamp with control, the two-tailed paired t test was used. Simple linear and multiple linear regression analyses were performed for the various metabolic parameters and the standard errors of the estimate were calculated (43) . The data are presented as mean± I SD in the text and mean± 1 SE in the figures.
Results
The mean age of the seven healthy male subjects in the hyperglycemic clamp protocol was 24±4 yr. The circulating substrate concentrations during control and both levels of the hyperglycemic clamp are shown in Fig. 1 . During the hyperglycemic clamp an increase in arterial lactate was observed; while the arterial FFA fell significantly.
Hemodynamics. The mean heart rate and mean arterial pressure were 65±7 bpm and 90±8 mmHg during control (fasting), 66±7 bpm and 92±8 mmHg during level I of the glucose clamp and 70±8 bpm and 92±7 mmHg during level II of the clamp. The coronary sinus flow determined by a thermodilution technique was 10 1±26 ml/min for control, 97±20 ml/min for level I and 104±26 ml/min for level II. The calculated myocardial oxygen consumptions for these periods were 12.5±2.7 ml/min, 11.1+2.4 ml/min, and 11.7±2.9 ml/min, respectively. There were no significant differences between control and level I or II of the glucose clamp for any of these parameters.
Myocardial substrate extraction. The myocardial extractions of glucose, lactate and FFA are presented in Fig. 2 . The glucose and FFA extractions were calculated from the A -CS difference. Since [U-'3C]lactate was infused as a tracer, an isotopic extraction ratio was obtained for lactate. Significant increases in glucose and ['3C]lactate extraction were demonstrated during the hyperglycemic clamp. Glucose extraction rose from a control value of 0.15±0.13 to 0.54±0.14 ,gmol/ml during level II of the glucose clamp (P < 0.005). The isotopic lactate extraction increased from 0.24±0.12 to 0.45±0. 13 ,tmol/ml, respectively, (P < 0.01). Myocardial FFA extraction fell significantly during both levels I and II of the glucose clamp, 0.18±0.05 umol/ml for control and 0.08±0.04 and 0.04±0.04 Mmol/ml for levels I and II, respectively, (P < 0.01).
Using the blood flow obtained by the coronary sinus thermodilution technique, one can calculate the myocardial uptake expressed as micromoles per minute for these major substrates. During hyperglycemia, the changes observed in the myocardial extractions (micromoles per milliliter) were also seen in the calculated uptakes. The myocardial glucose uptake was 14 Circulating insulin values. In this study we made no attempt to suppress endogenous insulin excretion during the glucose clamp. The mean fasting arterial plasma insulin concentration was 5±3 1,U/ml, during level I and level II of the clamp these values rose to 19±10 ,uU/ml (P < 0.05) and 30±8 tsU/ml (P < 0.01), respectively. Determinants of glucose uptake. Simple linear regression analysis showed a positive correlation between the circulating glucose concentration and myocardial glucose uptake, r = 0.57, P < 0.001 (Fig. 3) . The relationship between arterial FFA and myocardial glucose uptake is shown in Fig. 4 ; a highly significant inverse correlation was observed, r = -0.66, P < 0.001. Multiple linear regression analysis was performed to evaluate the influence ofarterial FFA and arterial glucose as important variables on myocardial glucose uptake. The t value was 0.716 (P = 0.488) for arterial glucose and -2.560 (P = 0.016) for arterial FFA. This implies that the arterial FFA concentration is the more predictive variable in determining myocardial glucose uptake.
Net alanineflux. The mean arterial blood alanine concentration was 243±54 nmol/ml during control and both levels of the clamp. During the two levels of hyperglycemia, there were no significant changes in the arterial alanine concentration. In one subject A -CS blood alanine concentrations showed minimal myocardial extraction, and in the other six subjects there was evidence of alanine production during fasting conditions; the mean A -CS alanine difference was -9±8 nmol/ ml. There were no statistically significant changes in net myocardial alanine flux during the glucose clamp; -14+10 nmol/ ml during level I (P = 0.19) and -15±10 nmol/ml during level II (P = 0.1 1). In this study, simple linear regression analysis did not indicate any significant correlations between A -CS alanine and glucose extraction (r = -0.06, P = NS) nor A -CS alanine and ['3C]lactate extraction (r = -0.12, P = NS).
Oxygen extraction ratios (OERs). The A -CS oxygen content difference was 11.97±0.40 ml/100 ml during control, 10.95±0.85 (P < 0.05) and 11.13±0.51 ml/100 ml (P < 0. Exogenous glucose oxidation. Glucose was specifically labeled with 14C in the sixth position; this carbon is removed in the citric acid cycle (44) . By measuring the myocardial production of '4C02, the amount of exogenous glucose undergoing immediate oxidation can be determined. Fig. 5 ,umol/ml, P < 0.01 compared with control). However, despite this increase, only 32± 10% of the glucose extracted was oxidized immediately. The oxygen equivalent can be calculated for the amount of exogenous glucose oxidized based on the '4CO2 data. In contrast to the OERs based on the A -CS glucose difference, the '4C02 data indicate that the contribution ofexogenous glucose to myocardial oxidative metabolism was only 3±4% during fasting conditions, 6±6% during level I and increased to 24±7% during level II of the glucose clamp (P = 0.005). Although there was a significant increase during hyperglycemia, these results imply that the immediate oxidation of exogenous glucose provides only a quarter of the energy required for myocardial oxidative metabolism even under optimal conditions for glucose metabolism.
Myocardial lactate release. L-[U-13C]Lactate was used as a
tracer and an isotopic extraction for lactate was determined. In all subjects the isotopic extraction was greater than the chemical lactate difference during both fasting (control) and hyperglycemia. This finding indicates that the myocardium was releasing (producing) lactate (33, 34) . During level II of the glu- release. * ** §Significant change compared with control (P < 0.05, P < 0.01 and P < 0.005, respectively). cose clamp, there was a slight increase in lactate release compared with control and level I; this small increase was statistically significant at P < 0.01 (Fig. 6 ).
By infusing both [6-`'C]glucose and [U-'3C]lactate and measuring the specific activities ("IC) of glucose and lactate and the enrichment of [U-'3C]lactate in the artery and coronary sinus, we are able to quantitate the contribution ofexogenous glucose to lactate release. As shown in Fig. 6 , 40±30% of the lactate release was derived from exogenous glucose during control. These values were significantly increased during both level I and level II hyperglycemia (74±52%, P < 0.05, and 97±37%, P < 0.005, respectively).
Metabolicfate ofglucose. Fig. 7 presents the percentage of extracted glucose undergoing immediate oxidation, being converted and released as lactate or being stored as glycogen. During control conditions 9±10% of the extracted glucose was oxidized and 13±9% was converted and released as lactate. The remainder of the glucose extracted (78%) was assumed to be stored as glycogen.
During acute short-term hyperglycemia there was a significant increase in the contribution of exogenous glucose to lactate release (Fig. 6) . However, the percentages of the extracted glucose going to lactate during levels I and II of the glucose clamp were not changed significantly from control (13±9% vs. 9±3% and 11±6%, respectively, Fig. 7 ). The percentages of extracted glucose oxidized increased during hyperglycemia (13±11% during level I and 32±10% during level II). Despite the increase in glucose oxidation during level II, the majority of glucose extracted (57%) continued to be stored as glycogen during this phase of hyperglycemia.
Control subjects. derived from exogenous glucose. Only 3% of the exogenous glucose was oxidized. The CS -A "'CO2 difference did not change during the duration of our sampling period, i.e., 45-180 min after the initiation of the isotope infusion. Thus, these data imply that the increase in glucose oxidation observed during hyperglycemia was secondary to the metabolic changes introduced by the glucose clamp and not due to the duration of the isotope infusion.
Discussion
This is the first study that investigates myocardial glucose oxidation and utilization during acute short-term hyperglycemia in normal humans. Circulating glucose was elevated to two levels (level I-150 mg/100 ml and level II-190 mg/I00 ml), and the duration of each level was an hour. These glucose concentrations are similar to those after a carbohydrate meal; however the duration of hyperglycemia in this study was significantly longer than that observed postprandial in nondiabetics. In this study endogenous insulin was not suppressed and the arterial FFA were allowed to fall. Under these conditions, increases in myocardial glucose extraction were observed with each level of hyperglycemia. We also found that immediate oxidation of exogenous glucose was enhanced; however, during level II with circulating glucose levels of 190 mg/100 ml for an hour, the exogenous glucose oxidation only accounted for 25% of myocardial oxidative metabolism.
Previous studies have concluded that glucose contributes 15-55% of the energy needed for oxidative metabolism during fasting conditions and that this percentage increases to 65-100% during acute hyperglycemia (7) (8) (9) (10) (11) (12) (13) (14) (15) . These conclusions were based on OER data which were calculated from the A -CS glucose difference with the assumption that the entire A -CS difference was oxidized immediately. OERs calculated on the A -CS glucose differences in the present study give similar results, i.e., 17% during fasting conditions and 74% during level II hyperglycemia. However, since glucose was labeled with "'C, the amount of exogenous glucose being oxidized immediately could be calculated from the myocardial production of "'CO2. The (Fig. 6 ), therefore we believe that very little glycogen is being broken down and utilized under these conditions and that the triglyceride pools are probably the source of the remainder of the energy required for oxidative metabolism.
Infusing [6- ['3C]lactate data previously discussed suggest that pyruvate dehydrogenase activity is markedly increased during the hyperglycemic conditions of our study. Thus, we believe that this slight increase in lactate release is related to enhanced activity in the glycolytic pathway. During fasting conditions, we also found that < 50% ofthe lactate released was derived from exogenous glucose. However during both levels of hyperglycemia in this study, the contribution of exogenous glucose to lactate release significantly increased over fasting values (Fig. 6 ). This finding indicates that elevating glucose under the conditions of this study results in an increase in the relative contribution ofexogenous glucose to the total glycolytic carbon flux compared with fasting conditions.
After myocardial extraction, glucose is immediately phosphorylated. Glucose 6 -phosphate can enter several different metabolic pathways within the myocardial cell: conversion to pyruvate via glycolysis, conversion to ribose via the pentose pathway or conversion to glycogen (47, 48) . Pyruvate can undergo oxidative decarboxylation to acetyl-coenzyme A, which enters the citric acid cycle. The carbon in the sixth position on glucose is released in the citric acid cycle (44); thus, measuring myocardial 14C02 production allows us to quantitate the amount of exogenous glucose undergoing immediate oxidation. Pyruvate can also be converted to lactate and released from the cell. As described above, L-[U-'3C]lactate was used as a tracer in order to measure myocardial lactate release. The '3C enrichment oflactate and the specific activities (14C) ofglucose and lactate were determined to quantitate the contribution of exogenous glucose to lactate release. Pyruvate can also be converted to alanine via a transaminase reaction (48, 49) . Alanine concentrations were measured in this study. In these young healthy subjects, we found that the myocardium was producing a small amount of alanine. The specific activity (14C) of alanine was not measured. However, if all the alanine produced was derived from exogenous glucose, this could only account for 3% of the extracted glucose during fasting and 2% during hyperglycemic conditions in this study.
Glucose 6-phosphate can also be converted to ribose via the pentose pathway (50) . Since the carbon in the first position on glucose is released as CO2 in this pathway (44) , the amount of glucose being shunted through this metabolic pathway would not be detected in our experiments using D-[6-'4C]-glucose. However, animal experiments have shown that in the adult, noninfarcted myocardium the metabolic activity in the pentose pathway is very low (44, 48, 51) .
Glucose may also be stored in the myocardium as glycogen. The enzymes involved in the regulation of the rate of glycogen synthesis and breakdown are controlled by various hormones and intracellular metabolic intermediates (52) (53) (54) (55) .
In the fasting state with high circulating FFA concentrations, myocardial glycogen stores increase (55) . Animal studies have also shown that with exercise or ischemia the myocardial glycogen content falls significantly (56) (57) (58) (59) . Under basal conditions, myocardial glycogen has a slow turnover of 5-6 h (60, 61). The stability ofthe CS -A 14CO2 difference over the 3 h of isotope infusion in the two control subjects also implies a slow glycogen turnover during fasting conditions. We have evidence that the 14C label has equilibrated with the CO2 pool (33) ; however, since glycogen has such a slow turnover, we do not believe that the 14C label has achieved a steady state with the glycogen pool. Therefore the amount of 14C label that remains unrecovered is assumed to be incorporated into myocardial glycogen. During hyperglycemia, endogenous insulin increases. Studies in skeletal muscle and myocardium have shown that insulin increases the activity of glycogen synthase, the rate-limiting enzyme for muscle glycogen synthesis (62) (63) (64) . Because of the activation of the enzyme glycogen synthase, the myocardial glycogen pool size probably increased under the conditions of our experiment. The amount of 14C label that remained unrecovered during level I and level II ofthe glucose clamp would argue in favor ofan expansion of the glycogen stores. A limitation of this investigation in humans is that the myocardial glycogen content could not be measured. However using the isotopic data, we can make the following calculations. The difference between the total lactate release and the lactate coming from exogenous glucose presumably represents the contribution of glycogen to nonoxidative glycolysis. This same relative ratio ofexogenous glucose to endogenous glucose (glycogen) is probably entering glycolysis and being oxidized. Based on these assumptions and that the myocardial blood flow is 1 ml/min per g, estimations ofglycogen synthesis and breakdown can be made. During fasting control conditions, we calculated that in 1 h 7.0 umol/g of glycogen (expressed as glucosyl units) was synthesized from the exogenous glucose extracted and that 1.7 gmol/g of glycogen was broken down and appears as unlabeled lactate release and an additional 2.2 5mol/g was oxidized. Therefore, in 1 h under these control conditions, there was a net increase of 3.1 gmol/g of glycogen. Similar calculations suggest that during the 1 h of level I hyperglycemia, there was a net increase of 1 1.1 smol/g and for level II a net increase of 18.4 ,umol/g. Thus, these estimations imply that over the course of this study (3 h), the glycogen content increased by - 33 ,mol/g of myocardium.
Biopsies performed during cardiac surgery in humans and animal studies have shown that the myocardial glycogen stores are increased after glucose infusions (23, 25, 26, 65) . Lolley and his colleagues used a high fat diet and a glucose-insulinpotassium infusion to elevate myocardial glycogen in patients prior to cardiac surgery and reported a 47-gmol/g (93 vs. 46 ,umol/g) difference in the glycogen contents from biopsies obtained immediately before cardiac bypass (24). Thus, the estimated increase in glycogen stores in this study is well within the range observed by other investigators. In the normal physiologic state, hyperglycemia of 190 mg/ 100 ml is transient and not sustained for hours. However in the diabetic state with prolonged hyperglycemia and elevated circulating FFA, the myocardial glycogen content can be markedly increased compared with nondiabetics (66) .
In the fasting state circulating FFA are a major determinant of myocardial glucose utilization (7, 48, 67, 68) . Previous studies in fasting humans have reported highly significant inverse correlations between arterial FFA concentrations and myocardial glucose extraction (1 1, 33) . We have previously shown that FFA concentrations are also inversely correlated with the percentage of extracted glucose undergoing oxidation in fasting human subjects (33). Randle et al. have shown in isolated heart experiments that glucose uptake and oxidation are both inhibited by high circulating concentrations ofFFA at several enzymatic steps in the glycolytic pathway (69) . The supply of ATP in the cell regulates the various pathways. Ifthe cell is utilizing FFA, the ATP level is high and the level of acetyl-coenzyme A increased. With high levels of acetyl-coenzyme A, the enzyme pyruvate dehydrogenase is inhibited. This enzyme is involved in the oxidative decarboxylation of pyruvate; thus, inhibition of this enzyme blocks entry of glucose into the citric acid cycle. Also, when the myocardium is actively utilizing FFA, there is a build-up of citrate. Citrate inhibits the enzyme phosphofructokinase in the glycolytic pathway. When this latter enzyme is blocked, glucose 6-phosphate accumulates in the cell. As this occurs, hexokinase is inhibited and the rate of glucose phosphorylation declines. In the present investigation there was a fall in FFA concentration which would remove these inhibitory effects and result in an increase in glucose uptake and the glycolytic rate.
In the present study the circulating glucose concentration was elevated and stabilized; and endogenous insulin was not suppressed and therefore increased during the glucose infusion. In addition to enhancing glucose uptake and metabolism, insulin also inhibits lipolysis in vivo (70) . Thus the circulating concentrations ofFFA fell significantly during our study (Fig. 1) . Multiple linear regression analysis was performed to determine the relationship between arterial glucose and arterial FFA with myocardial glucose uptake. This analysis showed that in our study the arterial FFA were significantly inversely correlated with glucose uptake, and that the addition of arterial glucose did not increase the level of significance. Barrett et al. (71) also reported that the arterial FFA suppression was more important than hyperglycemia in the regulation of myocardial glucose uptake. In conscious dogs, Barrett and his colleagues compared myocardial glucose uptake during a euglycemic insulin clamp with and without Intralipid infusion to raise FFA, with glucose uptake during a hyperglycemic clamp using somatostatin administration to inhibit endogenous insulin. These investigators found that glucose uptake was markedly enhanced during the insulin clamp when lipolysis was suppressed and the FFA concentrations were lower. Hyperglycemia, by itself, had little influence on glucose uptake. Myocardial glucose oxidation was not assessed in their study.
The major metabolic pathways linking carbohydrate and amino acid metabolism include the conversion of pyruvate to alanine and a-ketoglutarate to glutamic acid (49) . Previous studies have shown that there is significant net production of alanine and net uptake of glutamate by the myocardium (72) (73) (74) . The amounts of alanine produced and glutamate extracted were significantly higher in subjects with ischemic heart disease compared with those without coronary artery disease (72) (73) (74) . Thomassen et al. reported that myocardial alanine production and glutamate extraction were also positively correlated with glucose and lactate extraction (74) . In the present study the mean A -CS alanine difference was -9±8 nmol/ml during control. During level I and level II of the glucose clamp, there was a slight but not statistically significant increase in alanine production. No correlation was found between myocardial alanine flux with glucose or lactate extraction in our study. Glutamate concentrations were not measured. Our findings may differ from those of Thomassen et al. (74) because of subject selection. In the present study only healthy young normal male subjects (mean age 24±4 yr) were included while Thomassen and his colleagues included subjects (mean age 54±10 yr) with chest pain whose diagnostic coronary arteriograms demonstrated no significant lesions. Thus, the relationship between this transaminase reaction and glycolysis may be related to cardiac disease or aging.
In summary, this study demonstrates that despite a marked increase in myocardial glucose extraction during acute hyperglycemia, exogenous glucose oxidation only accounts for less than one-third of myocardial oxidative metabolism. During short-term periods of elevated circulating glucose (i.e. 2 h), there is evidence of increase in the contribution of exogenous glucose to the glycolytic carbon flux; however, the majority of exogenous glucose is probably stored as glycogen.
